α-galactosidase inhibitor; pharmacological chaperone. Inhibits galactosidase alpha (GLA), which interacts with SARS-CoV-2 Nsp14. Gordon et al. bioRxiv, Mar 23 2020, https://doi.org/10.1101/2020.03.22.002386.
- Applications:Approved drug (U.S.) that could be repurposed
Biochemicals & reagents
Migalastat (1-deoxygalactonojirimycin) competitively inhibits alpha-galactosidase with an IC50 = 40 nM (1) and it assists with lysosomal delivery of unstable proteins and therefore is a pharmacological chaperone for treatment of lysosomal storage disorders such as Fabry disease (2).